SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there

A chemosensitivity marker in SCLC, untested in its neuroendocrine relatives

SLFN11 is highly expressed in SCLC, and its expression has been reported to predict sensitivity to DNA-damaging agents there. Whether it carries the same meaning in the other lung NENs was not known. The authors stated that its role in typical and atypical carcinoids (TC and AC) and in LCNEC is unknown, and set out to measure it across those histologies alongside SCLC in one series.

This is a correlative survey rather than a treatment trial, and the published abstract reports no therapy-response or treatment-outcome data. What it measured instead was where SLFN11 sits across the neuroendocrine spectrum, and whether that expression tracks with the clinicopathologic and molecular features already used to classify these tumours.

361 tumours scored by IHC against a seven-marker panel

The investigators measured SLFN11 by immunohistochemistry, reported as an H-score from 0 to 300, in 361 tumours: 127 typical carcinoids, 35 atypical carcinoids, 152 LCNEC and 47 SCLC. SLFN11 staining was integrated with Ki67, pRb, cMYC, DLL3, ASCL1, HNF1a and OTP, and with the NEUROD1, ASCL1, POU2F3 and YAP1 (NAPY) transcription-factor panel, in which an H-score above 50 defined the dominant subgroup for each tumour.

Clinicopathologic data and survival were analysed alongside the staining, with the median SLFN11 expression used as the cut-off for the survival analysis. The published abstract does not report whether this panel or cut-off was tested against an independent cohort, so the associations below describe this one series.

Expression climbs steeply from carcinoids through LCNEC to SCLC

SLFN11 expression differed across histologies (p < 0.001). The median H-score was 0 in typical carcinoids (range 0 to 20) and 0 in atypical carcinoids (range 0 to 40), rising to 2.49 in LCNEC (range 0 to 250) and 35 in SCLC (range 0 to 240), a gradient that follows the same order these tumours are already ranked in by proliferative grade.

Across all four histologies, SLFN11 correlated positively with Ki67, the standard proliferation marker (R² = 0.187). The abstract reports this correlation across the whole cohort rather than broken out separately within each histology.

ASCL1-high tumours carry more SLFN11 in carcinoids and LCNEC, a trend in SCLC

In typical and atypical carcinoids, SLFN11 expression was enriched in A1 subgroup tumours, which are known for ASCL1 expression (p = 0.035), and was not correlated with OTP, HNF1A, CD44 or SSTR2A expression. In LCNEC, expression was higher in ASCL1-high tumours (median 17.2, range 0 to 162.5, versus lower expression outside that subgroup; p = 0.003) and correlated with cMYC expression (p = 0.024), but not with pRb or DLL3 status.

In SCLC, the authors reported a trend toward higher expression in ASCL1-high tumours without reaching statistical significance. This is the same direction seen in carcinoids and LCNEC, but the weakest of the three, despite SCLC being the histology in which SLFN11 is already best established.

Above-median expression nearly halved the risk of death, in SCLC only

SLFN11 expression was not prognostic in typical or atypical carcinoids, nor in LCNEC: in those three histologies, tumours with higher and lower expression showed no difference in survival.

In SCLC, expression at or above the median value was associated with longer overall survival: 13.9 months compared with 6.8 months (hazard ratio 0.48, 95% CI 0.26 to 0.90; p = 0.020). The SCLC subgroup numbered only 47 tumours, and the confidence interval on that hazard ratio is correspondingly wide; the finding is a prognostic association in one cohort, not yet a validated predictor of benefit from any specific treatment.

“SLFN11 exp was associated with ASCL1 exp in all lung NENs.”Scattolin et al., Lung Cancer (2026)

A marker still without a defined role outside small cell lung cancer

The authors concluded that SLFN11 expression in lung neuroendocrine neoplasms follows the order SCLC, then LCNEC, then typical and atypical carcinoids, and that it correlates with Ki67 and with ASCL1 expression throughout. No treatment-response or outcome data tied to SLFN11 status were reported outside the SCLC survival analysis, and the abstract does not say whether the cut-offs were confirmed in an independent cohort.

They also stated that the role of SLFN11 in carcinoids and LCNEC remains to be defined, so its value as a treatment-selection marker outside SCLC is still an open question. In SCLC, SLFN11 expression is already reported to predict sensitivity to DNA-damaging agents; this series adds a prognostic association to that picture, without addressing whether SLFN11 status should change which treatment a patient receives.